Novel prostaglandin derivatives
    34.
    发明授权
    Novel prostaglandin derivatives 失效
    新型前列腺素衍生物

    公开(公告)号:US4182773A

    公开(公告)日:1980-01-08

    申请号:US816207

    申请日:1977-07-15

    摘要: What is disclosed are prostaglandin-analogous cyclopentane derivatives of the formula I ##STR1## wherein R.sup.1 is hydrogen or a linear or branched, saturated or unsaturated aliphatic or cycloaliphatic radical having from 1 to 8 carbon atoms, or an araliphatic radical having from 7 to 9 carbon atoms, or a physiologically tolerable metal, NH.sub.4 or substituted ammonium ion derived from a primary, secondary or tertiary amine;R.sup.2 is a linear or branched, saturated or unsaturated aliphatic hydrocarbon radical having from 1 to 8 carbon atoms;R.sup.3 is hydrogen or a R.sup.4 CO group wherein R.sup.4 is a hydrogen atom or a linear or branched alkyl group having up to 10 carbon atoms;A is a saturated, linear or branched alkylene group having from 2 to 5 carbon atoms, and a process for the manufacture thereof.

    摘要翻译: 公开的是具有式I的前列腺素类似环戊烷衍生物,其中R 1是氢或具有1至8个碳原子的直链或支链,饱和或不饱和的脂族或脂环族基团,或具有7至9个 碳原子或生理上可耐受的金属,NH 4或衍生自伯,仲或叔胺的取代的铵离子; R2是具有1至8个碳原子的直链或支链饱和或不饱和的脂族烃基; R3是氢或R4CO基,其中R4是氢原子或具有至多10个碳原子的直链或支链烷基; A是具有2至5个碳原子的饱和直链或支链亚烷基及其制备方法。

    Cyclopentane derivatives
    35.
    发明授权
    Cyclopentane derivatives 失效
    环戊烷衍生物

    公开(公告)号:US4083990A

    公开(公告)日:1978-04-11

    申请号:US698843

    申请日:1976-06-23

    CPC分类号: C07C405/00

    摘要: The present invention relates to novel not naturally occurring 10,11-dihydro-derivatives of prostaglandins of the A-series as well as a process for their preparation. The compounds of the invention have an antiprostaglandin effect and may be used as medicaments for the inhibition or suppression of pharmacological properties of the prostaglandins.

    摘要翻译: 本发明涉及A系列前列腺素的新型非天然存在的10,11-二氢衍生物及其制备方法。 本发明的化合物具有抗前列腺素效应,可用作抑制或抑制前列腺素药理学性质的药物。

    Pharmacologically active O-acyl-2,3-diaryl-3-halogeno-acryl-aldoximes
    40.
    发明授权
    Pharmacologically active O-acyl-2,3-diaryl-3-halogeno-acryl-aldoximes 失效
    药理活性的O-酰基-2,3-二芳基-3-卤代丙烯酰基肟

    公开(公告)号:US4056629A

    公开(公告)日:1977-11-01

    申请号:US716277

    申请日:1976-08-20

    CPC分类号: C07D417/04

    摘要: A medicament consisting of or containing an O-acyl-2,3-diaryl-3-halogeno-acrylaldoxime of the formula I ##STR1## in which X represents a chlorine or bromine atom, R stands for an alkyl, alkenyl, alkoxy, alkenoxy or alkylamino group having from 1 to 12 carbon atoms each, or for an aryl, aryloxy, arylalkyl, arylalkoxy, arylamino or arylalkylamino group substituted optionally by 1 or 2 alkyl groups each having from 1 to 6 carbon atoms, and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are identical or different, each representing a hydrogen atom, a halogen atom or an alkyl or alkoxy group having each from 1 to 6 carbon atoms, a process for preparing them and a method for the treatment of disorders of the purine metabolism.

    摘要翻译: 由式I(I)的O-酰基-2,3-二芳基-3-卤代 - 丙烯醛肟组成或含有其中X表示氯或溴原子的药​​物,R代表烷基,烯基, 或具有1至12个碳原子的芳基,芳氧基,芳基烷基,芳基烷氧基,芳基氨基或芳基烷基氨基,任选地被1或2个具有1至6个碳原子的烷基取代的烷氧基,链烯氧基或烷基氨基, R2,R3和R4相同或不同,各自表示氢原子,卤素原子或具有1至6个碳原子的烷基或烷氧基,其制备方法和治疗嘌呤病症的方法 代谢。